Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

Research and Innovation Action for improving the clinical outcome of malignant brain tumours in adults and children with tailored immunotherapy treatments

A Horizon Europe project funded by the EU, Switzerland, and the UK

PROJECT FACTS

million in funding
0
years of duration
0
partners participating
0
clinical centres conducting trials
0
I/O treated patients
> 0

What is GLIOMATCH?

GLIOMATCH is a Horizon Europe project with the ambition of pioneering targeted brain cancer treatment. KU Leuven leads the GLIOMATCH consortium uniting over a dozen pan-European partners from 10 different member states.    

KU Leuven is home to the Laboratory for Precision Cancer Medicine, attached to the Translational Cell and Tissue Research Unit of the Department of Imaging and Pathology and the Leuven Institute for Single-cell Omics, focused on precision matching of cancer treatments with patients.

In alignment with Europe’s Beating Cancer Plan, GLIOMATCH addresses the EU Cancer Mission‘s four objectives: understanding cancer, prevention and early detection, diagnosis and treatment, and quality of life for patients and their families

Brain tumours are amongst the most lethal forms of cancer types, causing profound distress for individuals and their families and imposing a burden on communities and healthcare systems. By making technology for customised treatments available to clinicians, GLIOMATCH aims to alleviate this burden.

There is an unmet need for adults and children suffering from brain cancer

The prospects for patients of all ages suffering from glioblastoma are bad and have barely improved over the past three decades.

There are significant challenges to finding the best treatment for patients

Patients and tumours are extremely heterogeneous and clinicians lack valuable information required for matching patients with the most effective treatments.

GLIOMATCH's solution: a therapy selection platform

A platform for clinicians, which continuously integrates and evaluates years worth of data from glioblastoma patients, can significantly improve patient care.

We will use state-of-the-art technology and join forces to better understand how immunotherapy can be harnessed to treat malignant brain tumours in adults and children.

Prof. Frederik De Smet from KU Leuven,
GLIOMATCH project coordinator

 

News

July 2024 is Glioblastoma Awareness Month

Glioblastoma Awareness Day (GBM Day) on 17 July 2024 aimed to raise awareness and support for those affected by glioblastoma, an aggressive brain tumour. GLIOMATCH’s month-long campaign is summarised in this article, highlighting the critical need for further research.

Read More »

GLIOMATCH Partners